Developing Thermally Stable Dry Powder Vaccine Platforms Via Spray Drying Tailored for Inhalation Delivery **

点击翻译按钮获取中文摘要

Innovations in vaccine development greatly benefit public health, by pursuing new and**improved biologics, and re-envisioning new delivery routes though changes in their**formulation and manufacture. The proposed research will advance recent progress made by**an interdisciplinary team of scientists in designing new thermally stable vaccine platforms**targeted against tuberculosis and influenza infection, where the temperature sensitive**biologics will be stabilized by encapsulation in suitable carriers, thereby removing the**necessity for costly and often unavailable refrigeration equipment in their storage and**transport. The proposed project brings together chemical engineering and biomedical**expertise to understand and implement industrially relevant drying techniques that will**produce thermostable dry powder vaccines retaining their immune-boosting potency as seen**in their original liquid form, yet now can be stored at room temperature for 3 months without**loss in activity whereas liquid losses in potency occur in less than 1 week. Spray-drying these**vaccine powders under optimized conditions results in a product designed for delivery to the**lung by inhalation, boosting their effectiveness against lung-borne infections like tuberculosis**and influenza, while avoiding the complex logistics of re-constituting dried vaccines in liquid**media prior to administration. The research will produce optimal examples of thermostable**dry powder tuberculosis and influenza vaccines, relating their physical and biological**properties to engineering principles on particle formation and particle aerodynamics in the**human respiratory system. The new knowledge will be transferred to appropriate**pharmaceutical experts for the benefit of Canadas public health.